Navigation Links
La Crosse Encephalitis IgM

ProductsLa Crosse Encephalitis IgM
Company ARUP Laboratories
Item La Crosse Encephalitis IgM
Features 
Description ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' clients include more than half of the nation's university teaching hospitals and children's hospitals, major commercial laboratories, military and government facilities, and major clinics.
Info ARUP Laboratories
Customer Service: (800) 522-2787
Web site: http://www.aruplab.com

Related medicine products :

1. Encephalitis, La Crosse IgG (CSF)
2. Encephalitis, La Crosse IgM (CSF)
3. Encephalitis, La Crosse IgG
4. Encephalitis, La Crosse IgM
5. La Crosse Encephalitis IgG
6. La Crosse Encephalitis, IgM (CSF)
7. La Crosse Encephalitis IgG (CSF)
8. California Encephalitis Antibody, IgG by IFA, CSF
9. California Encephalitis Antibody, IgM by IFA, CSF
10. California Encephalitis Antibody, IgG by IFA, Serum
11. California Encephalitis Antibody, IgM by IFA, Serum
Full-Height Radiation Barriers provide full-body shielding and reduce eye strain during extended procedures....
RayShield Frame Mounted Overhead Lead Acrylic Barriers are offered in a choice of three sizes: 60 cm x 80 cm ( 24" x 32") wide, 60 cm x 50 cm( 24" x 20") wide. Lead acrylic windows of 0.5 mm and 1.0 ...
... prevent lower body exposure to scattered radiation. Dual ... where X-ray fluoroscopy is used. These shields are ... C-arm fluoroscopy units are used. Three sizes of ... with a 17 cm wide mounting bracket that ...
Pregnancy Apron...
Medicine Products:
(Date:10/22/2014)... Shriners Hospitals for Children® and UK HealthCare have ... of Shriners Hospitals for Children - Lexington from 1900 ... of Kentucky Albert B. Chandler Hospital. The new facility ... operated by Shriners Hospitals for Children, and designed to ... families well into the future. , “The quality care ...
(Date:10/22/2014)... October 22, 2014 Best Cheap Hosting ... the world. The site has recently announced that iPower ... supplier for people from around the world. , “iPower ... operation today and is providing various kinds of useful ... company insists on offering excellent customer service and a ...
(Date:10/22/2014)... PA (PRWEB) October 22, 2014 Richard ... as an industry leader with over 25 years experience. ... team leader in the areas related to EDI, B2B ... Carlson is an Editorial Advisory Board member for Pharmaceutical ... Educator. Blue Fin Group is a management and ...
(Date:10/22/2014)... Tara Haelle HealthDay ... Binge drinking among young adult men may lead to increased ... drinking didn,t cause a similar rise in blood pressure for ... In fact, when young adult women drank lightly or moderately, ... the study found. "This finding parallels studies in older ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 The newly ... must-have source of thousands of facts, figures and forecasts ... and 68 medical sector forecast categories the Worldwide ... global, regional and national views on the worldwide medical ... , The report gives you data for 2010-2019, covering ...
Breaking Medicine News(10 mins):Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 2Health News:Shriners Hospitals for Children - Lexington Announces Plan to Build New $47 Million Facility 3Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4
... Arthritis is the nation,s most common cause of ... projected to increase to 67 million by 2030, and ... activity as a result, according to the Centers for ... University of Missouri researchers found that adults with arthritis ...
... 8 Accuray,Incorporated (Nasdaq: ARAY ), a global ... first CyberKnife(R) Robotic Radiosurgery System in,the Kingdom of Saudi ... Hospital and Research Center in Riyadh. It is the ... region., King Faisal Specialist Hospital, the leading medical ...
... ... Industry, PORTLAND, Maine, Oct. ... drugs for pets, reports that,the current Bear market will not hamper its ... owners are committed to their pet,s welfare and want the same,standard of ...
... Weight Watchers,International, Inc. (NYSE: WTW ) today ... as its President, North America, effective November,3, 2008. ... and general management experience, will oversee the Company,s,North ... and licensing businesses and will be reporting to ...
... or "the Company") (OTC Bulletin Board: SOBM) is ... on October 2, 2008 to officially,appoint Lionel Choong ... Consulting Services Agreement to be effective as of ... appointed to the Company,s audit,committee. An earlier news ...
... FRANCISCO, Oct. 8 Dr. Jane Hightower -- widely,acknowledged ... in patients who regularly consume certain types of fish ... failed to inform and protect,the public from the risks ... seafood. Dr. Hightower has released a new book, Diagnosis:,Mercury: ...
Cached Medicine News:Health News:Incorporating education in exercise programs increases benefits for arthritis patients 2Health News:First CyberKnife in Saudi Arabia to be Installed at Prestigious King Faisal Specialist Hospital and Research Center 2Health News:First CyberKnife in Saudi Arabia to be Installed at Prestigious King Faisal Specialist Hospital and Research Center 3Health News:First CyberKnife in Saudi Arabia to be Installed at Prestigious King Faisal Specialist Hospital and Research Center 4Health News:Maine Company/Startup Undaunted by Bear Market 2Health News:Weight Watchers Names Steven C. McCormick as President, North America 2Health News:Weight Watchers Names Steven C. McCormick as President, North America 3Health News:Sinobiomed Directors Confirm Hiring of New Chief Financial Officer 2Health News:New Evidence Highlights Dangers of Mercury Toxicity in Fish 2
(Date:10/22/2014)... and AUSTIN, Texas ... and PureMHC LLC today announced they have entered ... novel antibody-based immunotherapies designed to target cancers. ... phosphorylated peptides displayed on the surfaces of tumor ... tumor targets (PTTs), derived from proteins that play ...
(Date:10/22/2014)... , Oct. 22, 2014  AcelRx Pharmaceuticals, ... that results from the  IAP310 study have been ... (RAPM), a peer-reviewed journal with broad, multidisciplinary ... trial evaluating the safety and efficacy of Zalviso, ... system (SSTS), for the treatment of post-operative pain ...
(Date:10/22/2014)... Calif. , Oct. 22, 2014 /PRNewswire/ ... ), a biopharmaceutical company leading the discovery ... today announced that it has demonstrated human ... ongoing clinical study evaluating RG-101, a wholly-owned, ... treatment of hepatitis C virus infection ("HCV").  ...
Breaking Medicine Technology:Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8